| Followers | 161 |
| Posts | 7125 |
| Boards Moderated | 0 |
| Alias Born | 04/26/2010 |
Tuesday, October 31, 2023 8:46:25 AM
who writes: So far, Dr. Missling has successfully funding the company, built shareholder value, and seen every clinical trial succeed.
This is not supported by the facts. How has he successfully funded the company? Because its doors are not yet shut? How hard is it to dilute shareholders? The share price is the final arbiter, and the market, both of which prove that Anavex has gone from 30 bucks on a one day sugar high (it never deserved to ever be remotely that high) all the way back to $5.50, its current price, a failed share price of around an 80% decrease. The best one can say is that he has overseen this preciptous disaster drop but he also oversaw its climb as well.
So, the fact is, after 10 years, and programs still existant, we really don't know how any of this will turn out.
10 years is a very long time, but you will say hey, a decade at the helm is par for the course, etc....
The bloom is off the rose. Had you gone back ten years ago, when the share price was 5 bucks reverse split adjusted, and said the share price would appreciate 50 cents over the next 10 years, there would not be a single shareholder. Even instituitions which blindly throw money at this sector, would have sold.
And measured against true inflation of the last decade, or measured against thousands of other companies in the biotech sector or the market in general, whose share prices have soared, the company is a fail. A failure so far, and the market agrees. These are the facts, not rose colored glasses "facts."
To deny the endless broken promises, and the fact that the market does not buy the company as having made much progress at all (50 cents worth in an entire decade), is to ignore reality as so many LONG GONE shareholders who have lost precipitous sums, have commented. You haven't been around long in this stock, and are willing to forgive anything and everything.
Bottom line is the stock is not lower because of a liquified stock market, where money is everywhere still. The FED has said they were gonna drain the market but that has largely not taken place and in fact as rates have climbed the FED has simultaneously reliquified the market. If that liquidity leaves the market, and if AVXL has not provided the market with crystal clear data, the share price will go much much lower. If you like that investment proposition, @God Bless you. Facts are the facts. The precipitous decline the past 2.4 years in the share price is a fact. You don't get to make up the facts.
This is not supported by the facts. How has he successfully funded the company? Because its doors are not yet shut? How hard is it to dilute shareholders? The share price is the final arbiter, and the market, both of which prove that Anavex has gone from 30 bucks on a one day sugar high (it never deserved to ever be remotely that high) all the way back to $5.50, its current price, a failed share price of around an 80% decrease. The best one can say is that he has overseen this preciptous disaster drop but he also oversaw its climb as well.
So, the fact is, after 10 years, and programs still existant, we really don't know how any of this will turn out.
10 years is a very long time, but you will say hey, a decade at the helm is par for the course, etc....
The bloom is off the rose. Had you gone back ten years ago, when the share price was 5 bucks reverse split adjusted, and said the share price would appreciate 50 cents over the next 10 years, there would not be a single shareholder. Even instituitions which blindly throw money at this sector, would have sold.
And measured against true inflation of the last decade, or measured against thousands of other companies in the biotech sector or the market in general, whose share prices have soared, the company is a fail. A failure so far, and the market agrees. These are the facts, not rose colored glasses "facts."
To deny the endless broken promises, and the fact that the market does not buy the company as having made much progress at all (50 cents worth in an entire decade), is to ignore reality as so many LONG GONE shareholders who have lost precipitous sums, have commented. You haven't been around long in this stock, and are willing to forgive anything and everything.
Bottom line is the stock is not lower because of a liquified stock market, where money is everywhere still. The FED has said they were gonna drain the market but that has largely not taken place and in fact as rates have climbed the FED has simultaneously reliquified the market. If that liquidity leaves the market, and if AVXL has not provided the market with crystal clear data, the share price will go much much lower. If you like that investment proposition, @God Bless you. Facts are the facts. The precipitous decline the past 2.4 years in the share price is a fact. You don't get to make up the facts.
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
